EGFR and colorectal carcinoma: Using eight BRAFV600E CRC cell lines collected at four different times (up to 72 h) with BRAF inhibitor, BRAF inhibitor + EGFR inhibitor or BRAF inhibitor + SRC inhibitor, we found that SRC inhibition did not significantly impact rebound of ERK phosphorylation (Extended Data Fig. 4a,b).